IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 677-689

  Erb, Holger H H ^a   Langlechner, Regina V ^a   Moser, Patrizia L ^b   Handle, Florian ^a   Casneuf, Tineke ^c   Verstraeten, Karin ^c   Schlick, Bettina ^d   Schäfer, Georg ^a   Hall, Brett ^c   Sasser, Kate ^c   Culig, Zoran ^a   Santer, Frédéric R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Oncotyrol Center for Personalized Cancer Medicine   (Austria)

Author keywords

IFN 2; IL6; Inflammation; IRF9; Prostate cancer

Indexed keywords

ALPHA2 INTERFERON; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 6; MESSENGER RNA; SILTUXIMAB; STAT1 PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84886428517     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0222     Document Type: Article

References (50)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT & Thompson TC 1999 Elevated levels of circulating interleukin-6 and transforming growth factor-b1 in patients with metastatic prostatic carcinoma. Journal of Urology 161 182-187. (doi:10.1016/S0022- 5347(01) 62092-5)
2. Akira S, Taga T & Kishimoto T 1993 Interleukin-6 in biology and medicine. Advances in Immunology 54 1-78.
3. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I & Eisenberger M 2010 Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research 16 203-211. (doi:10.1158/1078-0432.CCR-09-2514)
4. Borden EC 1984 Progress toward therapeutic application of interferons, 1979-1983. Cancer 54 2770-2776. (doi:10.1002/1097- 0142(19841201) 54:2C!2770::AID-CNCR2820541425O3.0.CO;2-0)
5. Bracarda S, Eggermont AM & Samuelsson J 2010 Redefining the role of interferon in the treatment of malignant diseases. European Journal of Cancer 46 284-297. (doi:10.1016/j.ejca.2009.10.013)
6. Caraglia M, MarraM, Pelaia G,Maselli R, Caputi M, Marsico SA & Abbruzzese A 2005 a-Interferon and its effects on signal transduction pathways. Journal of Cellular Physiology 202 323-335. (doi:10.1002/jcp.20137)
7. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA et al. 2007 The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26 2822-2832. (doi:10.1038/sj.onc.1210097)
8. Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA & Culig Z 2008 Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Advances in Experimental Medicine and Biology 617 547-555. (doi:10.1007/978-0-387-69080-3- 56)
9. Chang AY, Fisher HA, Spiers AS & Boros L 1986 Toxicities of human recombinant interferon-a2 in patients with advanced prostate carcinoma. Journal of Interferon Research 6 713-715. (doi:10.1089/jir. 1986.6.713)
10. Conze D,Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P & Rincon M 2001 Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Research 61 8851-8858.
11. Culig Z 2011 Cytokine disbalance in common human cancers. Biochimica et Biophysica Acta 1813 308-314. (doi:10.1016/j.bbamcr.2010.12.010)
12. Culig Z, Steiner H, Bartsch G & Hobisch A 2005 Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry 95 497-505. (doi:10.1002/jcb.20477)
13. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H et al. 2005 Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Research 33 e175. (doi:10.1093/nar/gni179)
14. Darnell JE Jr, Kerr IM & Stark GR 1994 Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 1415-1421. (doi:10.1126/science. 8197455)
15. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C & Hauschild A 2012 Management of pegylated interferon a toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy 12 1087-1099. (doi:10.1517/14712598.2012.694421)
16. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M & Murphy GP 1999 Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41 127-133. (doi:10.1002/ (SICI) 1097-0045(19991001) 41:2!127::AID-PROS7O3.0.CO;2-H)
17. Feng S, Tang Q, Sun M, Chun JY, Evans CP & Gao AC 2009 Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Molecular Cancer Therapeutics 8 665-671. (doi:10.1158/1535-7163. MCT-08-0823)
18. Frank DA 1999 STAT signaling in the pathogenesis and treatment of cancer. Molecular Medicine 5 432-456.
19. Frank DA 2003 StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treatment and Research 115 267-291.
20. Giri D, Ozen M & Ittmann M 2001 Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 159 2159-2165. (doi:10.1016/S0002-9440(10) 63067-2)
21. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 93 1687-1697. (doi:10.1093/jnci/93.22.1687)
22. Gutterman J & Quesada J 1981 Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer. Texas Reports on Biology and Medicine 41 626-633.
23. Hobeika AC, Subramaniam PS & Johnson HM 1997 IFNa induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14 1165-1170. (doi:10.1038/sj.onc. 1200939)
24. Hobeika AC, Etienne W, Torres BA, Johnson HM & Subramaniam PS 1999 IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. Journal of Interferon & Cytokine Research 19 1351-1361. (doi:10.1089/107999099312812)
25. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G & Culig Z 2000 Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Journal of Pathology 191 239-244. (doi:10.1002/1096- 9896(2000) 9999:9999!::AID- PATH633O3.0.CO;2-X)
26. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H & Culig Z 2001 Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clinical Cancer Research 7 2941-2948.
27. Hoefer J, Schafer G, Klocker H, Erb HH, Mills IG, Hengst L, PuhrM&Culig Z 2012 PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. American Journal of Pathology 180 2097-2107. (doi:10.1016/j.ajpath.2012.01.026)
28. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D et al. 2002 Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-a-2b and docetaxel. Cancer Research 62 5720-5726.
29. Hudak L, Tezeeh P, Wedel S, Makarevic J, Juengel E, Tsaur I, Bartsch G, Wiesner C, Haferkamp A & Blaheta RA 2012 Low dosed interferon a augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 72 1719-1735. (doi:10.1002/pros.22525)
30. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B & Speed TP 2003 Summaries of Affmetrix GeneChip probe level data. Nucleic Acids Research 31 e15. (doi:10.1093/nar/gng015)
31. Ishiguro H, Akimoto K, Nagashima Y, Kagawa E, Sasaki T, Sano JY, Takagawa R, Fujinami K, Sasaki K, Aoki I et al. 2011 Coexpression of aPKClambda/iota and IL-6 in prostate cancer tissue correlates with biochemical recurrence. Cancer Science 102 1576-1581. (doi:10.1111/j. 1349-7006.2011.01972.x)
32. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
33. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, Reddy M, Puchalski T, Safer K, Prabhakar U et al. 2011 The anti-interleukin-6 antibody Siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 71 1455-1465. (doi:10.1002/pros.21362)
34. Kirkwood J 2002 Cancer immunotherapy: the interferon-a experience. Seminars in Oncology 29 18-26. (doi:10.1053/sonc.2002.33078)
35. Li J, Hu XF & Xing PX 2005 CNTO-328 (Centocor). Current Opinion in Investigational Drugs 6 639-645.
36. Luker KE, Pica CM, Schreiber RD & Piwnica-Worms D 2001 Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Research 61 6540-6547.
37. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC et al. 2001 T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. PNAS 98 14565-14570. (doi:10.1073/pnas.251140998)
38. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H & Murai M 2000 Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clinical Cancer Research 6 2702-2706.
39. Okamoto M, Lee C & Oyasu R 1997 Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research 57 141-146.
40. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T & Djeu JY 2006 Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25 6113-6122. (doi:10.1038/sj.onc.1209632)
41. Rane JK, Pellacani D & Maitland NJ 2012 Advanced prostate cancer - a case for adjuvant differentiation therapy. Nature Reviews. Urology 9 595-602. (doi:10.1038/nrurol.2012.157)
42. Reich NC & Liu L 2006 Tracking STAT nuclear traffic. Nature Reviews. Immunology 6 602-612. (doi:10.1038/nri1885)
43. Sica G, Fabbroni L, Castagnetta L, Cacciatore M & Pavone-Macaluso M 1989 Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urological Research 17 111-115. (doi:10.1007/ BF00262031)
44. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ & Pastan I 1990 Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Research 50 7786-7788.
45. SiegsmundMJ, YamazakiH &Pastan I 1994 Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. Journal of Urology 151 1396-1399.
46. Smyth GK, Yang YH & Speed TP 2003 Statistical issues in microarray data analysis. Methods in Molecular Biology 224 111-136.
47. Talloen W, Clevert D-A, Hochreiter S, Amaratunga D, Bijnens L, Kass S & Goehlmann HW 2007 I/NI-calls for the exclusion of non-informative genes: a highly effective filtering tool formicroarray data. Bioinformatics 23 2897-2902. (doi:10.1093/bioinformatics/btm478)
48. Trikha M, Corringham R, Klein B & Rossi JF 2003 Targeted anti-interleukin- 6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research 9 4653-4665.
49. Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A & Zoon KC 2009 IRF9 is a key factor for eliciting the antiproliferative activity of IFN-a. Journal of Immunotherapy 32 803-816. (doi:10.1097/CJI.0b013e3181ad4092)
50. Weihua X, Hu J, Roy SK,Mannino SB & Kalvakolanu DV 2000 Interleukin-6 modulates interferon-regulated gene expression by inducing the ISGF3 gamma gene using CCAAT/enhancer binding protein-b(C/EBP-b) . Biochimica et Biophysica Acta 1492 163-171. (doi:10.1016/S0167- 4781(00) 00111-1)